Brief: Regeneron Announces Strategic Collaboration With Parabilis Medicines To Advance Novel Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
18/05/2026 12:01
May 18 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: REGENERON ANNOUNCES STRATEGIC COLLABORATION WITH PARABILIS MEDICINES TO ADVANCE NOVEL ANTIBODY-HELICON™ CONJUGATES ACROSS MULTIPLE THERAPEUTIC AREAS REGENERON PHARMACEUTICALS INC: AGREEMENT PROVIDES FOR PARABILIS TO RECEIVE $125M FROM REGENERON REGENERON: DEAL INCLUDES ABOUT $2.2B IN ADDITIONAL POTENTIAL MILESTONE PAYMENTS PLUS TIERED ROYALTIES REGENERON PHARMACEUTICALS: UNDER TERMS, ADDITIONAL TARGETS MAY BE PURSUED UPON ADDITIONAL OPTION PAYMENTS FROM CO Source text: ID:nGNX5zPMMr Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement